Hoffmann-La Roche Overview

Trial Radar AI Insights

Roche

Hoffmann-La Roche, commonly known as Roche, operates as a global powerhouse in both pharmaceuticals and diagnostics, maintaining a dominant position in oncology, neurology, and ophthalmology. Founded in 1896 and headquartered in Basel, Switzerland, the company leverages its dual-track expertise to pioneer precision medicine, integrating diagnostic insights with targeted therapeutic interventions. Roche maintains a massive clinical footprint, currently managing a diversified portfolio of biologics, small molecules, and advanced RNA-based therapies.

• Company Snapshot: Founded 1896; HQ Basel, Switzerland; Public (RHHBY); https://www.roche.com
• Scale & Stage: Employees ~103,249; Market Cap $343.37B; Commercial stage
• Research Focus: Oncology (Solid and Hematologic), Neurology (Alzheimer’s, MS), and Ophthalmology
• Clinical Footprint: Active trials (lead sponsor): 203, Total participants: 119,841, Key geographies: United States, China, and Europe (Spain, Italy, France)

Therapeutic Focus

Roche prioritizes high-unmet-need areas where molecular biology and diagnostic data can drive superior clinical outcomes. The company’s strategy centers on transforming the standard of care in oncology through immunotherapies and bispecific antibodies, while expanding its reach into chronic and degenerative conditions such as Alzheimer’s disease and metabolic dysfunction-associated steatohepatitis (MASH).

• Primary Focus Areas:
• Oncology: Broad programs in breast, lung, and gastrointestinal cancers, utilizing checkpoint inhibitors (Atezolizumab) and PI3K alpha inhibitors (Inavolisib).
• Neurology: Development of brain-shuttle technologies for Alzheimer’s and next-generation B-cell therapies for Multiple Sclerosis.
• Metabolism & Cardiovascular: New growth pillars in obesity (GLP-1/GIP) and hypertension (RNAi).
• Strategy & Capabilities:
• Roche utilizes a "Brainshuttle" platform to improve the delivery of biologics across the blood-brain barrier, a key differentiator in its neurology pipeline.
• The company is aggressively pivoting into the obesity and MASH markets through recent acquisitions, aiming to compete in the high-growth cardiometabolic space with differentiated assets like CT-388 and Pegozafermin.

Hoffmann-La Roche Pipeline and Products

Marketed Products

Late-Stage Pipeline (Phase 2b+)

Early-Stage Pipeline Highlights

Roche is advancing several high-potential programs in the discovery and Phase I stages:

• Divarasib (KRAS G12C inhibitor): Currently in Phase III for 2L NSCLC but undergoing Phase I/II exploration for combinations with immunotherapy to move into frontline settings.
• Silent Rock (HS-10370): A KRAS G12D inhibitor licensed from Hansoh Pharma, targeting mutations previously considered "undruggable" in pancreatic and colorectal cancers.
• Emugrobart (Anti-myostatin): Investigated in Phase II to prevent lean muscle loss during intensive weight loss treatments (e.g., GLP-1 therapy) and for Spinal Muscular Atrophy.

Hoffmann-La Roche Clinical Trials Landscape

Trial StatisticsApply Below Filters

Roche maintains a massive clinical research infrastructure, acting as the lead sponsor for 203 active trials targeting approximately 119,841 participants across 14,739 global sites. The pipeline is heavily weighted toward late-stage development, with 90 trials currently in Phase III, supported by a robust early-to-mid-stage engine comprising 41 Phase I and 67 Phase II studies. This research effort reaches 136 sites in the United States and has significant depth in Spain, Italy, and Poland, plus 86 additional trials conducted as a collaborator.

Key Clinical Trial Updates

• Fenebrutinib (MS): In February 2026, the FENtrepid trial met its primary endpoint, making it the first investigational medicine in over a decade to demonstrate a reduction in disability progression for Primary Progressive Multiple Sclerosis (PPMS).
• CT-388 (Obesity): Following strong Phase II data showing 22.5% weight loss, Roche is initiating the ENITH Phase III program in Q1 2026 to evaluate the dual GLP-1/GIP agonist in obesity and Type 2 Diabetes.
• Tiragolumab (TIGIT): The SKYSCRAPER-01 study in lung cancer missed its primary overall survival endpoint; as of early 2026, Roche has discontinued development in several lung and GI settings.
• Gazyva (SLE): Results from the ALLEGORY trial were positive, supporting a planned regulatory filing for Systemic Lupus Erythematosus in the first half of 2026.

Business Insights and Analysis

Business Development

Roche utilizes strategic acquisitions and high-value licensing to fill pipeline gaps, particularly in metabolic and cardiovascular health.

• Metabolic Pivot: The $2.7B acquisition of Carmot Therapeutics (January 2024) and the $3.5B acquisition of 89bio (October 2025) secured CT-388 and Pegozafermin, respectively, positioning Roche as a major contender in obesity and MASH.
• Strategic Alliances: The company co-develops Zilebesiran with Alnylam and partners with Sarepta for the international distribution of the gene therapy Elevidys.
• Neurology Collaboration: Roche continues its long-term partnership with Ionis Pharmaceuticals, utilizing antisense technology to target intractable neurological and cardiometabolic diseases.

Financial Overview

Roche Holding AG is a blue-chip constituent of the global healthcare market with a market capitalization of approximately $343.37B as of February 2026. The company reports strong revenue growth driven by the "V-cluster" of products (Vabysmo, Veclury, and Venclexta) and its diagnostics division. Roche's strong cash flow supports an annual R&D investment that consistently ranks among the highest in the pharmaceutical industry.

Clinical Trial Participation Guide

To explore active opportunities for participation in Roche’s research programs, users can utilize the Trial Radar platform tools:

• Participation Assistant: Use the "Simplify" tool to understand complex study requirements, preview the enrollment process with "What to Expect", and verify initial requirements via the "Check Eligibility" feature.
• Contacts & Locations: Navigate to the specific tab on any trial page to find participating hospitals and clinics and contact study coordinators directly for more information.

Explore Hoffmann-La Roche clinical trials

Check out 50 of 288 studies.